Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Helmedix Launched with Start-up Investment from the MRCF

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
Company will develop therapeutic peptide drugs for the prevention and treatment of autoimmune disease.

Helmedix Pty Ltd was launched with start-up financing from Australia’s Medical Research Commercialization Fund (MRCF).

Based on intellectual property from the University of Technology Sydney (UTS)’s ithree institute, Helmedix will develop therapeutic peptide drugs for the prevention and treatment of autoimmune disease.

The ithree Institute research team led by Dr Sheila Donnelly has identified a number of immune modulating peptides derived from helminth parasites, one of which is effective in suppressing the inflammatory response of the host and has shown therapeutic potential in a mouse model of type 1 diabetes.

The immune modulating activity of these peptides indicates potential broader application in a variety other autoimmune diseases.

The MRCF has committed AU$1.25 million to progress lead optimization and pre-clinical development of the immune modulating peptides over the next two years.

Subject to meeting milestones, Helmedix will seek further investment or industry partnerships to move the helminth-derived peptides through clinical development as a treatment for autoimmune and inflammatory diseases.

Commenting on the new company, Stephen Thompson, Director of Helmedix and Partner at Brandon Capital, the venture capital firm that manages the MRCF, said “Helmedix is a great example of the type of early stage opportunity that the MRCF is set up to support. Its discoveries have broad potential to impact a number of autoimmune diseases and we look forward to working with the team to progress the technology further towards commercial development.”

Professor Ian Charles, Director of the UTS ithree institute, said that the institute’s significant expertise in infectious diseases caused by bacterial, viruses and parasites was helping understand the way in which the helminth parasite evades the sophisticated immune defence systems of its host, continuing “Understanding the mechanism by which the helminth parasites can persist in their host by regulating the immune system, and applying these mechanisms to the development of therapeutics for the prevention or treatment of autoimmune and inflammatory diseases, has huge potential.”

This is the first investment by MRCF in technology emerging from the ithree institute. The institute was launched in 2010 and joined the MRCF in 2011.

Commercialization of ithree’s technology is managed by UTS’s commercialization partner UniQuest, who led the effort to attract investment by MRCF into Helmedix.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Regulator of Immune Reaction Discovered
Calcium signal in cell nucleus regulates not only many brain functions but also defence reactions of the immune system.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Cell’s ‘Built-In Circuit’ Help Prevent Tumour Growth
Researchers have created cells with a 'built-in genetic circuit' that inhibits tumour growth.
Factors Behind Suppression of Stem Cell Mobilization Revealed
The findings could lead to improvements in transplantation therapy.
Common Virus Helps Fight Liver Cancer
Reovirus, a cause of childhood colds, stimulates the immune system to kill cancerous cells.
Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
T Cell Channel Could Be Targeted to Treat Cancers
Researcher identify ion-channel found within T cells that could be targeted to reduce development of neck and head cancers.
Targeting Pancreatic Cancer
Cutting-edge technology exploits cancer cells’ vulnerabilities to develop new treatments.
A Genome-wide View of Human DNA Viruses
In this study, Duplex sequencing was used to accurately analyse the genome-wide rate of spontaneous mutation of human adenovirus C5 (HAdv5).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!